| Name | Title | Contact Details |
|---|
Gundersen Lutheran Health Plan is a Onalaska, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Based in Denver, Cordant Health Solutions™ provides innovative tools for monitoring and managing behavioral health, chronic pain and criminal justice cases. Our unique programs include pharmacy, clinical laboratory and analytic tools that provide actionable information to protect prescribers, improve outcomes and contain costs. As a leader in rigorous quality and compliance standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved in the substance use disorder, criminal justice and pain management markets. Cordant offers unique risk assessment, monitoring and management tools through its integrated network of laboratories and high-touch pharmacies specializing in the management and dispensing of controlled substances and behavioral health medications. Cordant`s testing protocols and digital case-management tools help clients become more efficient and effective in assessing and managing risk, monitoring patient adherence and improving patient outcomes.
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Taylor and Associates is a Winterville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.